I still don’t understand why Crohn’s disease isn’t the #1 focus for the company. Very large numbers of otherwise healthy people would jump at being involved in a trial that might cure them. The results from the phase 2 trial are apparently unequivocal, total eradication of the disease within 30 days, clearly visually inspected.
No need for subjective surveys or multi year studies like back pain and heart.
It’s the easiest pathway to a clear successful trial, it’s the fastest pathway and the prospective market is massive.
I still don’t understand why Crohn’s disease isn’t the #1 focus...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.020(1.73%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.17 | $16.67M | 14.04M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 54704 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.020 ( 3.40 %) |
||||
| Open | High | Low | Volume | ||
| $1.21 | $1.21 | $1.17 | 2927691 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| MSB (ASX) Chart |